FDA and FTC warn Purecraft LLC over CBD products marketed with unapproved COVID-19 prevention and treatment claims.
What happened
FDA reviewed purecraftcbd.com on December 14, 2022, and FTC reviewed it on January 6, 2023; FDA also reviewed the company's Facebook and Instagram pages. The website offered CBD products and included blog and social media claims that CBD could prevent, treat, or reduce COVID-19 symptoms and affect SARS-CoV-2. FDA called the products unapproved new drugs and misbranded drugs, and FTC said the COVID-19 disease claims lacked competent and reliable scientific evidence.
What FDA found
The CBD products are unapproved new drugs because they are sold with COVID-19 claims without FDA approval.
FD&C Act section 505(a), 21 U.S.C. § 355(a)The products are misbranded, meaning their labeling is not compliant, under section 502 of the FD&C Act.
FD&C Act section 502, 21 U.S.C. § 352Introducing or delivering these products into interstate commerce is prohibited.
FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)The company advertised that its CBD products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. § 41 et seq.Deceptive claims about COVID-19 treatment, cure, prevention, or mitigation can bring civil penalties under the COVID-19 Consumer Protection Act.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA and FTC ask Purecraft LLC to immediately stop selling and claiming that these CBD products can mitigate, prevent, treat, diagnose, or cure COVID-19. Within 48 hours, the company must email FDA with the steps taken and email FTC certifying that it has ceased the unsubstantiated claims.
Who should pay attention
- CBD brands making health claims
- retailers and online marketplaces selling CBD
- advertising and marketing teams for supplement or drug products
This is a summary. Read the original letter on fda.gov.